RxDoctor Payments DataLook up a doctor →

Millard Collier Jr, MD

Family Medicine · Lithia Springs, GANPI 1306860044

Payments from drug & device makers

$49,873in general payments, 2019–2025

Across 621 payments — averaging $80.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$19K
  • Boehringer Ingelheim$10K
  • Pfizer$5K
  • UCB, Inc.$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • plus $9K from 40 others

What the payments were for

  • Consulting fees$5,25011%
  • Speaking & faculty fees$24,50549%
  • Travel & lodging$4,2859%
  • Food & beverage$15,08930%
  • Education$740%
  • Other$6711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,873 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$38,439
Medicare patients
94
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide205$221,297
JardianceEmpagliflozin107$124,225
FarxigaDapagliflozin Propanediol76$58,148
JanuviaSitagliptin Phosphate44$36,275
Invega SustennaPaliperidone Palmitate11$36,234
KerendiaFinerenone24$28,180
RybelsusSemaglutide14$28,073
EliquisApixaban30$25,560
MyrbetriqMirabegron14$16,639
GlyxambiEmpagliflozin/Linagliptin11$13,303
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen310$10,437
EdarbyclorAzilsartan Med/Chlorthalidone37$9,636
VascepaIcosapent Ethyl17$9,045
Janumet XrSitagliptin Phos/Metformin Hcl13$7,860
LinzessLinaclotide11$7,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$1,992$251,478233 claims
Boehringer IngelheimJardiance, Glyxambi$10,099$137,527118 claims
AstraZenecaFarxiga, Symbicort, Nexium$2,151$67,477110 claims
MerckJanuvia, Janumet Xr$78$44,13557 claims
Johnson & JohnsonInvega Sustenna$120$36,23411 claims
BayerKerendia$665$28,18024 claims
PfizerEliquis$4,994$25,56030 claims
Astellas Pharma US IncMyrbetriq$419$16,63914 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$77$9,63637 claims
AbbVieLinzess$355$7,07511 claims
GSKBreo Ellipta$156$6,99612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Lithia Springs

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →